There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) and Geron Corp (NASDAQ:GERN) with bullish sentiments.
Spring Bank Pharmaceuticals Inc (SBPH)
B.Riley FBR analyst Madhu Kumar reiterated a Buy rating on Spring Bank Pharmaceuticals Inc today and set a price target of $30. The company’s shares opened today at $14.17.
Kumar commented:
“Pharmaceuticals (SBPH) announced 2Q18 earnings, and the firm provided an update from the 100 mg dose cohort of lead asset, RIG-I agonist inarigivir, in the Phase IIa ACHIEVE trial in chronic hepatitis B virus (HBV) infection. We continue to consider SBPH a relatively undervalued name in the HBV therapy space, with the start of Phase IIb/III studies in early 2019 as a potentially positive catalyst. We thus reiterate our SBPH Buy rating and $30 price target.”
According to TipRanks.com, Kumar is a 5-star analyst with an average return of 28.8% and a 50.8% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Deciphera Pharmaceuticals Inc, and Clementia Pharmaceuticals Inc.
Currently, the analyst consensus on Spring Bank Pharmaceuticals Inc is a Strong Buy with an average price target of $32.50, a 129.4% upside from current levels. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $35 price target.
.
See today’s analyst top recommended stocks >>
Geron Corp (GERN)
B.Riley FBR analyst George Zavoico reiterated a Buy rating on Geron Corp yesterday and set a price target of $5.75. The company’s shares opened today at $3.54.
Zavoico said:
“Geron Corp. released its 2Q18 financial results and an update of corporate activities after markets closed on Tuesday, July 31. In a conference call to investors, Geron described their own decision-making process for three possible scenarios following a decision by Janssen Pharmaceuticals expected by the end of this quarter regarding continuation of the developmental collaboration for Geron’s telomerase inhibitor imetelstat. The three possible scenarios are: 1) Janssen opts in to continue the collaboration and Geron opts in to remain a developmental partner; 2) Janssen opts in to continue the collaboration and Geron opts out of remaining a developmental partner, and; 3) Janssen opts out and discontinue the collaboration.”
According to TipRanks.com, Zavoico is a 3-star analyst with an average return of 6.3% and a 44.4% success rate. Zavoico covers the Healthcare sector, focusing on stocks such as Cellular Biomedicine Group, Catalyst Biosciences Inc, and Actinium Pharmaceuticals.
Geron Corp has an analyst consensus of Moderate Buy, with a price target consensus of $5.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
